DMED whistleblower data analysis

As it relates to malignant neoplasms and Guillain-Barré syndrome (GBS)

This analysis assumes that the DMED query for the term Neoplasms, (ALL CANCERS) listed in Exhibit A on p. 9 of the Renz packet for speaking to Senators and Congressmen includes all malignant neoplasms (ALL CANCERS) and all benign neoplasms. The DMED data provided in Exhibit A came from Renz’s team of whistleblowers as described in his filed Case 2:21-cv-00702 Document 47 in the U.S. District Court ND of Alabama:

LT COL Theresa M. Long, LT COL Peter Chambers, 1LT Mark Bashaw and MAJ Samuel Sigoloff (the “Whistleblowers”). Whistleblowers are U.S. Army medical officers with regular authorized access to DMED. Each of them regularly accesses DMED as a part of their job. Each of the Whistleblowers independently queried the DMED database using the same queries. Each of the Whistleblowers obtained the same shocking results. Each of the Whistleblowers attempted to discredit and find an alternate explanation for the results, and each failed. The queries and results are reflected in the File. The File is populated exclusively with, and faithfully reflects, the DMED data. The Excel spread sheet file first presented to the Court on February 8, 2022 (the “File”) is now attached as Exhibit A to this Supplement.

I make this assumption from what I found on his website to compare to his evidence provided in Exhibit A:

Renz must be referring to another set of numbers related to Malignant Neoplasms with a SPIKE of 664% then the Percent Increase in 2021 for the line item denoted by Neoplasms, (ALL CANCERS) which states a 296% Increase in 2021 in Exhibit A. Initial deletions have been made and are indicated with a cross-out and additions with [] to understand implications. The final numbers included the (12/11) increase for rates to account for Renz stating that the 2021 reports queried only included results up to eleven months (apparently some only included data up to ten months). It would be helpful to know exactly what date range returned for each query as it relates to the 2021 (Partial Year) data.

Rounding the Earth @EduEngineer

@waynerohde @DrLoupis @NickKottenstet1 Please review what really happened with the data first.

campfire.wikiThe DMED Saga - Campfire Wiki

In my last column, An uncontrollable system, I estimated the lower bound of the Under Reporting Factor (URF) for Guillain-Barré syndrome (GBS) following a COVID-19 vaccine in VAERS could be as much as 185 (I updated the article noting that if 5% of those injured died from GBS as indicated in The Swine Flu Affair, therefore, the lower bound of the URF could be as low as 110). A sketch of the proof is as follows:

1. Senator Kennedy’s committee halted the 76 Swine Flu vaccination program in which only 54 cases of GBS had been reported following vaccination on 12/14/1976.

2. CDC active surveillance discovers around five-hundred cases such that Schonberger et all suggest the rate of GBS is one case per one hundred thousand vaccinated suggesting 48,000,000/100,000, 480 Americans developed GBS following vaccination. CDC tacitly admits URF is around 480/54, nine times and at least 24 Americans died from GBS.

3. Mike Wallace reports that 300 Americans died from GBS following a Swine Flu vaccine, therefore, the URF should be at least 8.8 x (300/24) which equals 110.

4. Noting that the Lancet reports that 25% of those who suffer from GBS will require a mechanical ventilator, the modern “iron lung”, and the Annals of Indian Neurology report that 12% of patients on ventilators will die then the URF could be as high as (1/.03) x 300 / 54 which equals 185.

I also report that VAERS has 895 reported US cases of GBS which includes 18 who died following COVID-19 vaccinations (a 2% mortality rate). This suggests that today’s COVID-19 vaccines have resulted in at least:

• 100,000 Americans may have been injured with GBS the expected injury rate could be around 1.64 cases per ten-thousand doses.

• 25,000 Americans may be on ventilators due to GBS

• 3,000 Americans may have died from GBS

• The estimated lower bound on liability could be $3,500,000 x 100,000 $350 billion

An uncontrollable system

This leads us to the following question:

Are the estimated 2021 rates of GBS injury per individual calculated from the Defense Medical Epidemiology Database, DMED, data provided by the three whistleblowers and made available by Attorney Tom Renz comparable to the estimated COVID-19 GBS vaccine injury rate?

For a deep dive into the data release and its implications please see Steve Kirsch’s article:

DMED data is explosive. Mainstream media has been ordered to ignore it.

The key points of Steve’s article are as follows:

1. The database query involves the total number of reports of inpatient and ambulatory medical data for 1,400,000 Active military members.

2. According to PolitiFact the partial 2021 reported events from the DMED queries were valid, but, the earlier numbers were corrupted from the last 5 years.

   Officials compared numbers in the DMED with source data in the DMSS and found that the total number of medical diagnoses from those years "represented only a small fraction of actual medical diagnoses." The 2021 numbers, however, were up-to-date, giving the "appearance of significant increased occurrence of all medical diagnoses in 2021 because of the underreported data for 2016-2020," Graves said.

3. The CDC apparently ignored the massive jumps in DMED reports until the whistleblowers showed increases in cases.

Wayne Rhode and I Discuss this DMED Analysis

Wayne Rohde and I Discuss this DMED Analysis on The Right on Point podcast, Nick Kottenstette-DMED.

The DMED Query for Neoplasms and malignant neoplasms

I will first focus on the reported rates for neoplasms, some of the listed malignant neoplasms, and GBS, as reported by the DMED whistleblowers before the corrupted data, was “fixed”.

First is a key definition for neoplasm from the National Cancer Institute:

An abnormal mass of tissue that forms when cells grow and divide more than they should or do not die when they should. Neoplasms may be benign (not cancer) or malignant (cancer). Benign neoplasms may grow large but do not spread into, or invade, nearby tissues or other parts of the body. Malignant neoplasms can spread into, or invade, nearby tissues. They can also spread to other parts of the body through the blood and lymph systems. Also called tumor.

Next, we observe the table provided in Exhibit A as it relates to Cancer. First, note that Renz incorrectly notes Neoplasms as (ALL CANCERS). Because we now know that

• Neoplasms (all cancers and benign tumors)

• Malignant Neoplasms (all cancers)

The first key assumption in this discussion is that the query for Neoplasms (ALL CANCERS) did not include benign neoplasms. If it did, then this discussion will be very different If one goes to the MSMR Vol. 28 No. 05 May 2021 p. 18 Table 1, we see that the query for Neoplasms (140–239; C00–D49) includes ICD-10 codes for benign neoplasms (D10-D36) and those of uncertain behavior (D37-D49) in which there were an average of 113,569 medical encounters, slightly less than the 114,645 medical encounters denoted by Renz as Neoplasms (ALL CANCERS).

Note that “Percent Increase in 2021” should have been denoted as (Partial Year) reports to Avg Injuries Per Year 2016-2020 ratio, we shall call this the whistleblower risk ratio (WBRR) for short. If WBRR is 1.0 then the number of reports for 2021 (Partial Year) is the same as the reports for Avg Injuries Per Year 2016-2020. When the WBRR is 1.0 the increase in cases is 0%. It is further assumed that the query in the past and for the partial listing of 2021 medical encounters for a given disease. Note that all medical encounters will be greater than or equal to the individuals affected by a given disease.

1. Neoplasms (ALL CANCERS):

   • Avg Injuries Per Year 2016-2020 of 38,678 medical encounters which are 4,588 [85,013] less than the medical encounters listed for all cancers [neoplasams] listed in the MSMR Vol. 28 No. 05 May 2021 p. 7 [p. 18 Table 1] which lists that for 2020 there were 43,266 [malignant neoplasms] [and 67,061 (listed on p. 6) + 3,242] benign neoplasms resulting in a total of 113,569] medical encounters of malignant neoplasms and 6,672 individuals affected [with cancer and at least an additional 43,840 with benign neoplasms] in which the ratio of individuals affected to medical encounters is (6,672/43,266) 15% [for cancer] [and (43,840/67,061) 65% for benign neoplasms]. Implying an annual rate of individual cancer in the troops of 15 x (38,678/1,400,000) percent which equals 0.41%. According to the CDC, the current rate of new cancers in the US is 0.44% of which the MSMR reports 100 x (6,672/1,400,000) percent which equals 0.48% of cases in 2020. This is consistent with the glitch explanation given by Graves in which the database query returned fewer medical encounters for 2016-2020 than reported in the MSMR.

   • The 2021 partial report of 114,645 cases implies an annual rate of individual cancer in the troops of (12/11) x 15 x (114,645)/1,400,000 percent which equals 1.3% which is 2.97 times the average rate of new cancers in the US.

   • Therefore, the lower bound for the WBRR for all malignant neoplasms should be revised down to 296% [(12/11)x(114,645/113,569)] 281% [1.1] due to the glitch. If the query was for all neoplasms then the WBRR lower bound should be further reduced to 0.94 due to the glitch. Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 648% [for cancer and 153% for benign neoplasms].

2. Malignant Neoplasms of Digestive Organs (US Cases are based on Table 1):

   

   • the lower bound for the WBRR for all Malignant Neoplasms of Digestive Organs (assumed Stomach and Colon and Rectum Cancers) should be revised down to 624% 1.09 due to the glitch. Reported cases appear to be reported at half the US rate; however, this is probably due to these cancers being more common in older Americans. Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 1,269%.

3. Malignant Neoplasms of Thyroid & Other Endocrine Glands (US Cases are based on Table 1):

   

   • the lower bound for the WBRR for all Malignant Neoplasms of Thyroid & Other Endocrine Glands should be revised down to 474% 0.98 due to the glitch. Reported cases for our troops do appear to be 168% of the US Rate (elevated). Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 476%.

4. Testicular Cancer (Amb) (US Case rates are available here):

   

   • the lower bound for the WBRR for all Testicular Cancers should be revised down from 369% to 0.92 due to the glitch. Reported cases for our troops do appear to be 870% of the US Rate (extremely elevated). Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 670%.

5. Ovarian Cancer (Amb) (US Cases are based on Table 1):

   

   • the lower bound for the WBRR for all Ovarian Cancers should be revised down from 209% to 0.96 due to the glitch. Reported cases for our troops do appear to be 115% of the US Rate (slightly elevated). Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 413%.

6. Breast Cancer (Amb) (US Cases are based on Table 1):

   

   • the lower bound for the WBRR for all Breast Cancers should be revised down from 536% to 1.06 due to the glitch. Reported cases for our troops do appear to be 90% of the US Rate (slightly lower). Note that the Medical Encounter ratio to Individuals Affected (ME/IA) is 1,026%.

7. Remaining malignant neoplasms

   1. The remaining top 4 malignant neoplasm reports from the 2021 MSMR reports for the 2020 troops (denoted “2020 MSMR”) are:

      1. Lymphoma and multiple myeloma (6,311 MEs, 598 IAs, 9% (IA/ME), 182% of the US Rate (significantly elevated))

      2. Leukemia (4,908 MEs, 303 IAs, 6% (IA/ME), 118% of the US Rate (elevated))

      3. Melanoma and other skin cancers (4,520 MEs, 1,901 IAs, 42% (IA/ME), 446% of the US Rate (significantly elevated))

      4. Brain cancer (2,375 MEs, 187 IAs, 8% (IA/ME))

      Are any of these cancers “off the charts” or did the whistleblowers query all neoplasms? What can we learn from the reported cancers on VAERS?

Neuromuscular & Skeletal Systems

1. GBS:

   • 2016-2020 avg. 73. Using the assumption that 50% of the individuals are impacted per report then this implies an annual rate of GBS in the troops of 5,000 x (73/1,400,000) per ten-thousand which equals 0.26 cases per ten-thousand (which is still 2.6 times greater than the often claimed rate of 0.1 cases per ten-thousand Swine Flu vaccinations).

   • The 2021 partial report of 403 over eleven months implies an annual rate of GBS in the troops of 5,000 x (403/1,400,000) x (12/11) per ten-thousand which equals 1.57 cases per ten-thousand (note that if every report is unique then the rate increases to 3.14 cases per ten-thousand, which is greater than our upper-lower bound limit of 2.8 we estimated for injuries per vaccination from the VAERS reports and URF of 185).

2. Other related injuries in the Renz Exhibit A:

   • I will plan to write on these and other items in a follow-up article.

Conclusion

A friend had asked me to look into the DMED whistle-blower data, I was motivated to see if it could help shine a light on the rate of GBS cases estimated from the 76 Swine Flu URF estimate between 110 and 185. The expected rate of GBS injury is estimated to be between 1.4-2.8 cases per ten thousand COVID-19 vaccinations. Unfortunately, I can not determine the IA/ME ratio from past MSMRs as they do not report on individuals affected by GBS. Assuming there was not an underreporting glitch in the past database query for the years 2016-2020 then the rate of GBS and an assumed nominal IA/ME ratio of 1/2 with a range of uncertainty of [1/5,1] then the whistleblower DMED data suggests:

1. 2016-2020 avg rate of 0.26 [0.1,0.52] cases per ten thousand individuals.

2. 2021 rate of 1.57 [0.63, 3.14] cases per ten thousand individuals.

The CDC claimed that their active surveillance data suggested that the 76 Swine flu vaccine caused 0.1 cases per ten thousand vaccinations. Due to the 60 minutes report by Mike Wallace of 300 alleged deaths of GBS following vaccination the rate of GBS was more likely between 1.25-2.1 cases per ten thousand vaccinations. Either using the VAERS and URF estimate or the DMED whistleblower data we have indications that the COVID-19 vaccines are as or more dangerous in terms of GBS than the 76 Swine Flu vaccine that was pulled from the American public after 48,000,000 vaccinations.

There does appear to have been a glitch in the database queries for past 2016-2020 data as it related to reported malignant neoplasms when compared to the MSMRs. Such anomalies have been suggested by Mathew Crawford in his past posts and he notes that the May 2022 Medical Surveillance Monthly Report (MSMR) is missing the usual snapshots of either the ambulatory or hospitalization data.

Did RTE's Investigation Force the DoD to Stop Publishing the Military's Health Data?

Due to the apparent database query glitches experienced by the whistleblowers for the 2016-2020 datasets and the apparent confirmation of the reported Medical Encounter data for malignant neoplasms I recommend the following revision should be made to Tom Renz’s initial assertion of this DMED data as follows:

Assuming no more than eleven months of data was returned in the presented database queries reported DMED data of [Medical Encounters] might suggest that the Percent Increase in 2021 [Whistle Blower Risk Ratio (WBRR), when compared to 2020, reported numbers published in the May 2021 MSMR] for:

• Neoplasms (ALL CANCERS) is 296% 1.10 [a 10% increase]

• Malignant Neoplasms of Digestive Organs (assumed Stomach and Colon and Rectum Cancers) is 624% 1.19 [a 19% increase with preliminary estimated rates 0.49 times the average rate of new digestive organ cancers in the US]

• Breast Cancers is 536% 1.16 [a 16% increase with preliminary estimated rates 0.98 times the average rate of new breast cancers in the US]

• Ovarian Cancers is 209% 1.05 [a 5% increase with preliminary estimated rates 1.25 times the average rate of new ovarian cancers in the US]

• Malignant Neoplasms of Thyroid & Other Endocrine Glands is 474% 1.07 [a 7% increase with preliminary estimated rates 1.83 times the average rate of new thyroid cancers in the US]

• Testicular Cancers is 369% 1.0 [indicating no increase with preliminary estimated rates 9.49 times the average rate of new testicular cancers in the US].

The MSMRs are invaluable in completing this analysis and I hope that we see a report of the final reported medical encounters and individuals affected for the 2021 ambulatory and hospitalization data in the near future to confirm these findings.